Treatment recommendations for the use of bone-targeted agents in 2011- report from the 6th annual bone and the oncologist New Updates meeting

Current Oncology

Volumn 19, Issue 5, 2012, Pages

  Kuchuk, I ^a   Paterson, A ^b   Amir, E ^c   Clemons, Mark ^a   Bouganim, N ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bone health; Bone metastases; Bone targeted agents; Cancer

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE TURNOVER; BRAIN METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOTHERAPY INDUCED BONE LOSS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; HUMAN; HYPERCALCEMIA; METASTASIS FREE SURVIVAL; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SPINAL CORD COMPRESSION;

EID: 84867046120     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1008     Document Type: Article

References (32)

1. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010;28:3582-90.
2. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. 2010;28:3577-81.
3. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91. [Erratum in: N Engl J Med 2009;360:2379]
4. Gnant M, Mlineritsch B, Stoeger H, et al. on behalf of Austrian Breast and Colorectal Cancer Study Group, Vienna. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the abcsg-12 randomised trial. Lancet Oncol 2011;12:631-41.
5. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396-405.
6. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8:R13. [Erratum in: Breast Cancer Res 2006;8:406]
7. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the zo-fast Study. Ann Oncol 2010;21:2188-94.
8. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: z-fast study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85.
9. LLombarto A, Frassoldati A, Paija O, et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: e-zo-fast 36-month follow up [abstract 213]. ASCO Breast Cancer Symp 2009;:. [Available online at: http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&conf ID=70& abstractID=40178; cited July 16, 2012]
10. Amir E, Ocaña A, Seruga B, Josse R, Clemons M. Medical oncology: zoledronic acid for breast cancer therapy-induced bone loss. Nat Rev Clin Oncol 2010;7:187-8.
11. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010;102:799-802.
12. Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 1993;260:626-7.
13. Mano H, Yuasa T, Kameda T, et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun 1996;223:637-42.
14. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress rank ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A 2000;97:7829-34.
15. Miyaura C, Kusano K, Masuzawa T, et al. Endogenous boneresorbing factors in estrogen deficiency: cooperative effects of il-1 and il-6. J Bone Miner Res 1995;10:1365-73.
16. Paterson AHG, Anderson SJ, Lembersky BC, et al. NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy-final analysis [abstract S2-3]. Presented at the 2011 San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 6-10, 2011. [Available online at: http://www. abstracts2view.com/sabcs11/view.php?nu=SABCS11L_835; cited December 7, 2012]
17. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study. J Clin Oncol 2010;28:5132-9.
18. Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (cmf). Osteoporos Int 2003;14:1001-6.
19. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-7.
20. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (ies): a randomised controlled study. Lancet Oncol 2007;8:119-27.
21. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011;22:2546-55.
22. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the sabre trial. J Clin Oncol 2010;28:967-75.
23. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-82.
24. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221-7.
25. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: bone health in cancer care. J Natl Compr Canc Netw 2009;7(suppl 3):S1-32.
26. Warr D, Johnston M, and members of the Breast Cancer Disease Site Group. Use of Bisphosphonates in Women with Breast Cancer. Practice Guideline Report 1-11. Ver. 2.2002. Toronto, ON: Cancer Care Ontario; 2002.
27. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44.
28. Ali SM, Demers LM, Leitzel K, et al. Baseline serum ntx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004;15:455-9.
29. Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer 2011;19:1687-96.
30. Clemons M, Dranitsaris G, Ooi W, Cole DE. A phase ii trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (sre) or progressive bone metastases (bm) despite standard bisphosphonate (bp) therapy. Breast Cancer Res Treat 2008;108:79-85.
31. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase ii trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006;24:4895-900.
32. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57. [Erratum in: J Clin Oncol 2004;22:1351]